- Guanfacine and Methylphenidate in the Treatment of Hyperactivity in Children with Pervasive Developmental Disorder
The Massachusetts General Hospital for Children at the Lurie Center is conducting a Research Study for children 5–14 years old who have Pervasive Developmental Disorders (autism, Asperger’ disorder, or PDD-NOS). If your 5-14 year old has autism, Asperger’ disorder, or PDD-NOS, he or she may qualify for a research study involving study medication and clinic visits with a child psychiatrist and qualified research staff at no charge. The purpose of this study is to find out if the medication, extended release guanfacine, is helpful for the treatment of hyperactivity and impulsiveness in children. Participation requirements and risks involved in this study will be disclosed prior to study enrollment. If you are interested in participating or would like more information, please contact us at (781) 860-1700 or LurieCenterResearch@partners.org.
Institution – MGH - Massachusetts General Hospital, Boston, MA; Lurie Center, Lexington, MA
Principal Investigator – Christopher J McDougle, MD
For further information about enrolling a patient in this trial, contact the person below.
Name – Jennifer E Mullett, RN
Email – LurieCenterResearch@partners.org
Phone – 781-860-1711